Federal State Budget Institution

Moscow, Russia

Federal State Budget Institution

Moscow, Russia
SEARCH FILTERS
Time filter
Source Type

Shuvalova M.P.,Federal State Budget Institution | Yarotskaya E.L.,Federal State Budget Institution Research | Pismenskaya T.V.,Federal State Budget Institution | Dolgushina N.V.,Federal State Budget Institution | Sukhikh G.T.,Federal State Budget Institution
Journal of Obstetrics and Gynaecology Canada | Year: 2015

In this review, we provide basic facts about maternity care services within the health care system in Russia. We give a short overview of such key aspects as the demographic situation, reproductive behaviour, regulatory framework for providing health care for women and children, maternal and perinatal mortality, and the availability of medical personnel.In 2012, Russia began registration of births in accordance with the WHO recommendations (births with weight ≥ 500 g at ≥ 22 weeks' gestation). Introduction of this new registration system increased the completeness and quality of the collected information and expanded possibilities for future international comparative assessments.A three-level system of specialized medical care has been introduced in Russia for women and newborns during pregnancy, childbirth, and the postpartum period. In 2014, the system included 1942 state (public) maternity hospitals providing 20 obstetric beds per 10 000 women aged 15 to 49 years. More than 100 perinatal centres (level III) are currently functioning in the country, with 32 new perinatal centres planned to open by 2016. The total number of obstetrician-gynaecologists in Russia is approximately 44 000, providing a ratio of 5.7 specialists per 10 000 women. The total number of midwives is 62 000, providing a ratio of 8.1 midwives per 10 000 women.In recent years we have succeeded in optimizing the maternity care system by increasing its accessibility and quality. This was achieved through qualitative and quantitative progress in the training of neonatologists, the development of intensive care technologies and neonatal critical care, capacity building of medical-genetic services and counselling, prenatal diagnosis, and the standardization of health care with data collection. © 2015 Society of Obstetricians and Gynaecologists of Canada.


PubMed | Federal State Budget Institution
Type: Journal Article | Journal: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians | Year: 2015

To investigate the role of matrix metalloproteinases (MMP-2, MMP-9) and their inducer (CD147) in premature rupture of membranes (PROM) at term labor.In a cross-sectional study, 24 women aged 19-39, with 37-40-week pregnancy, and no clinical and histological signs of chorioamnionitis, were divided into two groups with and without PROM. The histological and immunohistochemical study of the fetal membranes was performed with polyclonal rabbit antibodies to MMP-2/MMP-9 and monoclonal rabbit antibodies to CD147.The analysis of MMP revealed the increase of MMP-9 expression in the amniotic epithelium during premature membrane rupture both in rupture area, and beyond it, and increased MMR-2 expression in the mesodermal cells. We also found high level of CD147 in the amniotic epithelium in PROM group. The above-mentioned changes were found in all areas of fetal membranes, regardless of the rupture localization.The study results demonstrate the increased expression of MMR-2 and MMR-9, which regulate the catabolism of fetal membrane extracellular matrix proteins, in amniotic membranes of women with PROM at term labor. The increased expression of CD147 may be one of the mechanisms triggering PROM in the absence of infection.


PubMed | CJSC MiraxBioPharma, Federal State Budget Institution Research Center for Obstetrics, Federal State Budget Institution < >, Moscow State University and 2 more.
Type: | Journal: The EPMA journal | Year: 2015

The article presents the results of a clinical trial on the efficacy and safety of a novel pharmaceutical composition in the form of vaginal suppositories containing diindolylmethane in the course of cervical intraepithelial neoplasia (CIN) I-II conservative treatment. It offers an attractive drug therapy for more personalized prevention of cervical cancer.A total of 78 women of reproductive age were included. This was a multicenter, randomized, placebo-controlled, double-blind, parallel-group trial with efficacy determined by histological evaluation of cervical biopsies. The efficacy of active drug treatment (100 and 200mg/day) in both treatment groups was significantly higher in comparison with the placebo group, according to the primary efficacy end point (proportion of patients with complete CIN regression after 90-180days of the study drug treatment).The efficacies were 100.0% (confidence interval (CI) 95%: 82.35-100.00%), 90.5% (CI 95%: 69.62-98.83%), and 61.1% (CI 95%: 35.75-82.70%), for the high dose, low does, and placebo, respectively. Adverse events in the placebo group were reported in 22% of patients (CI 95%: 7.5-43.7%); in the first treatment group (100mg/day), adverse events were reported in 40.0% of patients (CI 95%: 21.1-61.3%); in the second treatment group (200mg/day), adverse events were reported in 42.0% of patients (CI 95%: 22.1-63.4%). The differences in side effects between treatment groups treated with the active drug and placebo were statistically significant. No serious adverse events were reported in any of the groups.Thus, the use of diindolylmethane in the form of intravaginal suppositories can be effective in patients with CIN I-II and is not accompanied by clinically significant side effects. This approach could be a better option for young women with CIN I-II as it takes in attention their reproductive plans.ID: ChiCTR-INR-15007497 (2 December 2015).


PubMed | Director of Federal State Budget Institution, Federal State Budget Institution and Federal State Budget Institution Research
Type: Journal Article | Journal: Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC | Year: 2015

In this review, we provide basic facts about maternity care services within the health care system in Russia. We give a short overview of such key aspects as the demographic situation, reproductive behaviour, regulatory framework for providing health care for women and children, maternal and perinatal mortality, and the availability of medical personnel. In 2012, Russia began registration of births in accordance with the WHO recommendations (births with weight 500 g at 22 weeks gestation). Introduction of this new registration system increased the completeness and quality of the collected information and expanded possibilities for future international comparative assessments. A three-level system of specialized medical care has been introduced in Russia for women and newborns during pregnancy, childbirth, and the postpartum period. In 2014, the system included 1942 state (public) maternity hospitals providing 20 obstetric beds per 10000 women aged 15 to 49 years. More than 100 perinatal centres (level III) are currently functioning in the country, with 32 new perinatal centres planned to open by 2016. The total number of obstetrician-gynaecologists in Russia is approximately 44000, providing a ratio of 5.7 specialists per 10000 women. The total number of midwives is 62000, providing a ratio of 8.1 midwives per 10000 women. In recent years we have succeeded in optimizing the maternity care system by increasing its accessibility and quality. This was achieved through qualitative and quantitative progress in the training of neonatologists, the development of intensive care technologies and neonatal critical care, capacity building of medical-genetic services and counselling, prenatal diagnosis, and the standardization of health care with data collection.


News Article | November 18, 2016
Site: www.prnewswire.co.uk

Laureates to be recognized by Research and Academic Leaders at Awards Ceremony on December 1st in Moscow The organizers of Prix Galien Russia have today released the nominees for the third edition of the Awards. The Prix Galien Russia Committee (or Jury) comprises 15 renowned leaders in biomedical research and academia and is responsible for evaluating nominees based on scientific files. Laureates will be honored at the Prix Galien Russia Awards Ceremony at Volkhonka Mansion, on the 1st of December 2016 The Prix Galien Russia Committee designates a laureate in 6 different categories by evaluating scientific applications files submitted by the candidates based solely on two questions: Frederic Boucheseiche, General Secretary of Prix Galien Russia, reiterated the uniqueness and importance of Prix Galien by emphasizing the fact that the Jury's decision is based only on scientific and medical criteria, that marketing and commercial considerations never enter into the Jury's decision, and by restating that pharmaceutical companies cannot sponsor the event. "Organizing an awards ceremony under such strict principles is extremely challenging, but this is the condition that guarantees the impartiality of the jury's decision. Prix Galien Russia uses the same strict criteria as in all other countries where the award is held, making its legitimacy indisputable." Frederic Boucheseiche. Nominees for the Prix Galien Russia 2016 Awards are: Development of a new generation of Antivirals of the family of azoloazines - Institute of Organic Synthesis OncoFinder platform for personalized selection of drugs in oncology - First Oncology Research and Advisory Center ImmunoQuantex  "Femoflor®"+    «ImmunoQuantex" - DNA-Technology LLC/ Federal State Budget Institution "Research Center for Obstetrics, Gynecology and Perinatology" Ministry of Healthcare of the RF Prix Galien Russia was inaugurated in Moscow in 2013 under the auspice of an exceptional awards committee composed of eminent specialists involved in the sphere of Russian and international pharmaceutical research. A Prix Galien Award is considered the biomedical industry's highest accolade and recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines. Around the world, Prix Galien rewards outstanding achievements in improving the global human condition through the development of innovative therapies. Created in France 40 years ago, Prix Galien has selection committees in 16 countries around the world.


On Thursday, December 1st 2016, the Prix Galien Russia Awards Committee honored excellence in research, development and innovation in the biopharmaceutical industry at its third awards ceremony. The gala dinner was held in the presence of Sergey Tsyb, Vice Minister of Industry and Trade of the Russian Federation, Natalia Sanina, First Vice Chairman of the State Duma Healthcare Committee; Mikhail Murashko, Head of Roszdravnadzor, National Service of Control in Healthcare, Sergey Muravev, Director of the Department of International Cooperation and Public Relations, and Igor Lanskoy, Advisor to the Minister of Health of the Russian Federation among others. For the third time in history, the Prix Galien Russia Awards Committee, a Jury of 15 unrivalled Russian scientists and doctors, including academicians of the Russian Academy of Sciences, recognized leading efforts in advancing the human condition through biopharmaceutical innovation in six categories: Best Orphan Drug, Best Pharmaceutical Agent, Best Biotechnology Product, Best Medical Technology, Best Research in Russia and Best Russian Product. The Prix Galien Russia 2016 awards were presented to the following winners: In the category of Best Orphan Drug the award was presented to Amgen's Blinatomubab, for the treatment of Philadelphia chromosome-negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab overcomes the effect of tumor escape from the immune system. Due to its unique mechanism of immune effect, blinatumomab does not inhibit hematopoiesis, this sets up blinatumomab from cytotoxic agents, exhibiting a myelosuppressive effect, which limits their therapeutic options. The Medal was presented to Oleg Paroshin, CEO of Amgen Russia by Ekaterina Zakharova, President of the Association of rare diseases. The 2016 Prix Galien Russia Award for Best Pharmaceutical Agent was presented to Janssen's (Pharmaceutical Companies of Johnson&Johnson) - Imbruvica® (Ibrutinib) for chronic lymphocytic leukaemia. Ibrutinib is the first BTK inhibitor to offer patients a novel, targeted treatment that combines unparalleled efficacy and good tolerability with the convenience of oral dosing. In the category of Best Biopharmaceutical Product, the 2016 Prix Galien Russia Award was presented to Bristol-Myers Squibb's Yervoy® (Ipilimumab) for treatment of previously treated unresectable or metastatic melanoma. The 2016 Prix Galien Russia Award for Best Medical Technology was presented to Abbott's Absorb Bioresorbable Vascular Scaffold. Absorb is the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Absorb is designed to open a blocked heart vessel in the same way as a traditional metallic stent and then dissolve naturally. In the category of Best Research in Russia the award went to Valery Charushin, Oleg Chupakhin and Vladimir Rusinov for their work on the development of a new generation of antivirals of the family of azoloazines. The 2016 Prix Galien Russia Award for Best Russian Product was presented to the DNA-Technology and Federal State Budget Institution "Research Center for Obstetrics, Gynecology and Perinatology" Ministry of Healthcare of the Russian Federation "Femoflor®"+"ImmunoQuantex®" for differential and complex diagnosis of different clinical condition connected with dysbiotic disorders and inflammatory conditions of the lower reproductive tract of women. On the occasion of World HIV day, the Jury also honoured E. Zvartau, E. Krupitsky, D.Lioznov, G.Woody, J. Samet with a special distinction for their work on the prevalence of HIV in vulnerable and special populations of the Russian Federation. Reading a letter received by Veronika Skvortsova, Igor Lanskoi, adviser to the minister declared that "for many years, this has been one of the most coveted awards in the field of biopharmaceutical research, opening new perspectives for the improvement of medical science". Michael Murshko, presenting the medal for Best Research in Russia declared "healthcare cannot develop without innovations and the Prix Galien award is a successful example of support for new improvements in biomedical science, the main purpose of which is to provide patients with quality and effective medical products". Representing the State Duma for the first time at the event, Natalia Petrovna Sanina declared "Prix Galien is not just an award, it is a movement aimed at searching for and promoting scientific innovations that contribute to people's health".


Blume-Peytavi U.,Charité - Medical University of Berlin | Lavender T.,University of Manchester | Jenerowicz D.,Poznan University of Medical Sciences | Ryumina I.,Federal State Budget Institution | And 3 more authors.
Pediatric Dermatology | Year: 2016

Background European roundtable meeting recommendations on bathing and cleansing of infants were published in 2009; a second meeting was held to update and expand these recommendations in light of new evidence and the continued need to address uncertainty surrounding this aspect of routine care. Methods The previous roundtable recommendations concerning infant cleansing, bathing, and use of liquid cleansers were critically reviewed and updated and the quality of evidence was evaluated using the Grading of Recommendation Assessment, Development and Evaluation system. New recommendations were developed to provide guidance on diaper care and the use of emollients. A series of recommendations was formulated to characterize the attributes of ideal liquid cleansers, wipes, and emollients. Results Newborn bathing can be performed without harming the infant, provided basic safety procedures are followed. Water alone or appropriately designed liquid cleansers can be used during bathing without impairing the skin maturation process. The diaper area should be kept clean and dry; from birth, the diaper area may be gently cleansed with cotton balls/squares and water or by using appropriately designed wipes. Appropriately formulated emollients can be used to maintain and enhance skin barrier function. Appropriately formulated baby oils can be applied for physiologic (transitory) skin dryness and in small quantities to the bath. Baby products that are left on should be formulated to buffer and maintain babies' skin surface at approximately pH 5.5, and the formulations and their constituent ingredients should have undergone an extensive program of safety testing. Formulations should be effectively preserved; products containing harsh surfactants, such as sodium lauryl sulfate, should be avoided. Conclusion Health care professionals can use these recommendations as the basis of their advice to parents. © 2016 Wiley Periodicals, Inc.


Pokrovskiy A.V.,Federal State Budget Institution
Vestnik Rossiiskoi Akademii Meditsinskikh Nauk | Year: 2012

This article is dedicated to diagnostics, prevention and surgical treatment of vascular complications of diabetes mellitus, particularly prevention of ischemic strokes and treatment of critical ischemia of lover limbs. The main tendency in treatment of brachiocephalic artery lesions nowadays is a surgical intervention in the latent stage of the disease. X-ray endovascular surgical techniques are being increasingly used to treat lesions of lower limbs arteries. Limb preservation is impossible without cooperation of many specialists. It's essential to perform carefiil out-patient follow up of the patient after vascular reconstructive surgery.


PubMed | Russian Childrens Hospital, Federal State Budget Institution, State Institution Medical Genetic Research Center and Russian National Research Medical University
Type: Journal Article | Journal: Journal of medical case reports | Year: 2016

Niemann-Pick disease type C is a rare metabolic disease characterized by progressive neurological deterioration with childhood onset, and often results in premature mortality. Niemann-Pick disease type C has an extremely heterogeneous clinical presentation with a wide range of visceral and neurological signs and symptoms that are not specific to the disease, and which progress over varied periods of time. The incidence and epidemiology of Niemann-Pick disease type C in Russia have not been characterized. We report the case of a Russian newborn with early-infantile onset Niemann-Pick disease type C who displayed prolonged neonatal jaundice and hepatosplenomegaly.A 5-year-old white boy born to non-consanguineous Russian parents was originally diagnosed with galactosemia at the age of 2months based on a raised blood galactose level. A galactose-free and lactose-free diet resulted in achievement of a normal galactose level, but hepatosplenomegaly and cholestatic signs persisted. Liver biopsy results hinted at possible Niemann-Pick disease type C, but differential diagnostic investigations for progressive familial intrahepatic cholestasis type 2 (Byler syndrome) indicated a heterozygous genotype suggestive of this disease. Further, progressive neurological symptoms prompted additional genetic analyses for possible Niemann-Pick disease type C, from which an as-yet unreported combination of known NPC1 gene mutations was identified, and a final diagnosis of Niemann-Pick disease type C was established. The patient subsequently developed typical neurological symptoms of early-infantile Niemann-Pick disease type C, including vertical supranuclear ophthalmoparesis and cerebellar ataxia. Miglustat therapy was initiated 2.5years ago, and some improvements in movement and speech have since been observed.This case illustrates the continued challenges associated with diagnosing Niemann-Pick disease type C based on the appearance of nonspecific cholestatic symptoms. Based on this case we recommend examination of all newborns and children who display unexplained cholestasis or isolated splenomegaly/hepatosplenomegaly during the first months of life for other signs of possible Niemann-Pick disease type C.


PubMed | University of Manchester, Hospital Infantil Universitario Nino Jesus, University of Nantes, Charité - Medical University of Berlin and 3 more.
Type: Journal Article | Journal: Pediatric dermatology | Year: 2016

European roundtable meeting recommendations on bathing and cleansing of infants were published in 2009; a second meeting was held to update and expand these recommendations in light of new evidence and the continued need to address uncertainty surrounding this aspect of routine care.The previous roundtable recommendations concerning infant cleansing, bathing, and use of liquid cleansers were critically reviewed and updated and the quality of evidence was evaluated using the Grading of Recommendation Assessment, Development and Evaluation system. New recommendations were developed to provide guidance on diaper care and the use of emollients. A series of recommendations was formulated to characterize the attributes of ideal liquid cleansers, wipes, and emollients.Newborn bathing can be performed without harming the infant, provided basic safety procedures are followed. Water alone or appropriately designed liquid cleansers can be used during bathing without impairing the skin maturation process. The diaper area should be kept clean and dry; from birth, the diaper area may be gently cleansed with cotton balls/squares and water or by using appropriately designed wipes. Appropriately formulated emollients can be used to maintain and enhance skin barrier function. Appropriately formulated baby oils can be applied for physiologic (transitory) skin dryness and in small quantities to the bath. Baby products that are left on should be formulated to buffer and maintain babies skin surface at approximately pH 5.5, and the formulations and their constituent ingredients should have undergone an extensive program of safety testing. Formulations should be effectively preserved; products containing harsh surfactants, such as sodium lauryl sulfate, should be avoided.Health care professionals can use these recommendations as the basis of their advice to parents.

Loading Federal State Budget Institution collaborators
Loading Federal State Budget Institution collaborators